Preclinical studies using genetic CaMKII inhibition or peptide inhibitors (like autocamtide inhibitory peptide (AIP) and CaMKII inhibitor peptide (CaMKIIN) have shown improved cardiac function and reduced arrhythmias in HF models [22]. The gene discussed is CAMK2N2; the disease is hydrops fetalis.